Clinical Trial Update: Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor [Phase 2]

View source ↗

Summary

Results from a Phase 2 trial of nilotinib in patients with pigmented villonodular synovitis and diffuse-type tenosynovial giant cell tumor have been posted (com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pigmented Villonodular Synovitis
• Tenosynovial Giant Cell Tumor Diffuse Type

Drugs mentioned

• Tasigna (nilotinib)

Snippet

Sponsor: Andrew J. Wagner, MD, PhD | Conditions: Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor | Phase 2 | Status: COMPLETED | Results posted: 2015-06-25